吡嗪酰胺不同给药频次的效果及药效学评价

Clinical effects and pharmacodynamic evaluation of pyrazinamide at different medication frequencies in treatment of primary pulmonary tuberculosis

目的分析吡嗪酰胺不同给药频次(1.5 g,1次/d、0.5 g,3次/d)治疗初治肺结核的效果和综合评价,为临床合理使用吡嗪酰胺提供参考。方法选取2017年3~9月收治的肺结核初治患者90例,采用《中国结核病防治规划实施工作指南》规定的标准短程化疗方案[2HRZE/4HR(H:异烟肼,R利福平,Z吡嗪酰胺,E盐酸乙胺丁醇)]。按照随机表分为A组(吡嗪酰胺1.5 g,1次/d,39例)和B组(吡嗪酰胺0.5 g,3次/d,51例)。分析2组患者不良反应发生率、高尿酸发生率及临床治疗有效率。结果2组患者不良反应发生率比较,差异无统计学意义(P>0.05);2组患者高尿酸发生率差异无统计学意义(P>0.05);2组患者在8周、24周治疗有效率差异无统计学意义(P>0.05)。结论吡嗪酰胺0.5 g、3次/d给药,不会增加不良反应发生率,推荐1.5 g、1次/d给药。

Objective To investigate the clinical effects and pharmacodynamic evaluation of pyrazinamide at different medication frequencies in treatment of primary pulmonary tuberculosis effects,so as to provide reference for clinicians to use pyrazinamide rationally.Methods Ninety patients with primary pulmonary tuberculosis who were treated in our hospital from March 2017 to September 2017 were enrolled in the study,who were treated according to standard short-course chemotherapy scheme(2HRZE/4H R(H:isoniazid,R rifampicin,Z pyrazinamide,E ethambutol hydrochloride),and who were randomly divided into group A(pyrazinamide 1.5g once a day,n=39)and group B(pyrazinamide 0.5g,three times a day,n=51).The incidence rate of adverse reactions,the incidence rate of hyperuricemia and the effective rate were observed and compared between the two groups.Results There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).There was no significant difference in the incidence rate of hyperuricemia between the two groups(P>0.05).Moreover there was no significant difference in the effective rate at 8 weeks and 24 weeks after treatment between the two groups(P>0.05).Conclusion The pyrazinamide 0.5g/tid does not increase the incidence rate of adverse reactions,and pyrazinamide 1.5g/qd is recommended.